A Study of Neoadjuvant Chemotherapy Plus Anlotinib in Stage III(N2) Non-small-cell Lung Cancer

NCT04181372 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Stage III Non-small-cell Lung Cancer

Interventions

DRUG: Anlotinib hydrochloride
DRUG: platinum-based chemotherapy medicine

Sponsor

The First Affiliated Hospital of Guangzhou Medical University